Education
About Us
Working with TipRanks
Follow Us
Akero Therapeutics Inc (AKRO)
NASDAQ:AKRO
AKRO Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AKRO Stock 12 Month Forecast
Average Price Target
$72.71
▲(57.38% Upside)
| Highest Price Target$84.00 | Average Price Target$72.71 | Lowest Price Target$60.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$80
Buy
73.16%
Upside
Reiterated
09/18/25
Strategic Value and Market Positioning Drive Buy Rating for Akero TherapeuticsThis morning, Roche (SIX: RHHBY) announced that it has entered into a merger agreement to acquire 89bio (Nasdaq: the transacon is expected to close in Q4 2025. As a reminder, 89bio’s pegozafermin is an FGF21 analog in Phase III development for MASH, with topline data from (F4) expected in 2028, respecvely. Phase III study in severe hypertriglyceridemia are also ancipated in Q1 2026. We ulmately view the acquision as a strong strategic fit that broadens Roche’s CVRM pipeline and provides oponality for future combinaon approaches. Of note, the Company has historically been interested in targeng the FGF21 pathway (its FGFR1c/β-Klotho receptor agonist was terminated in Phase II for tachyphylaxis), has several incren agonists from the Carmot acquision, and recently iniated development of afimkibart (an-TL1A) in MASH.
Canaccord Genuity
$73
Buy
58.01%
Upside
Reiterated
09/18/25
Morgan Stanley
$84
Buy
81.82%
Upside
Reiterated
09/18/25
Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Akero Therapeutics (AKRO)We believe the deal provides positive readthrough to Akero's EFX highlighting further interest in the FGF21 mechanism as a target for treating MASH. 11:51 AM GMTM Update 2 M Inc (AKRO.O) Our PT is derived from a discounted cash flow (DCF) analysis, including risk-adjusted revenues for EFX in NASH that assumes a 12.5% discount rate and a 0% terminal growth rate. Risks to Upside n Better than expected clinical data.
H.C. Wainwright
$72
Buy
55.84%
Upside
Initiated
09/04/25
Bank of America Securities
$64
Buy
38.53%
Upside
Reiterated
08/25/25
Evercore ISI
$60
Buy
29.87%
Upside
Initiated
08/22/25
TD Cowen
$76
Buy
64.50%
Upside
Reiterated
08/08/25
J.P. Morgan
$69→$68
Buy
47.19%
Upside
Reiterated
05/14/25
Jefferies
$75
Buy
62.34%
Upside
Reiterated
05/13/25
Clear Street
$49
Buy
6.06%
Upside
Initiated
04/29/25
Westpark Capital
$72→$75
Buy
62.34%
Upside
Reiterated
02/28/25
Phillip Securities
$80
Buy
73.16%
Upside
Reiterated
02/28/25
UBS
$42→$109
Buy
135.93%
Upside
Reiterated
01/31/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$80
Buy
73.16%
Upside
Reiterated
09/18/25
Strategic Value and Market Positioning Drive Buy Rating for Akero TherapeuticsThis morning, Roche (SIX: RHHBY) announced that it has entered into a merger agreement to acquire 89bio (Nasdaq: the transacon is expected to close in Q4 2025. As a reminder, 89bio’s pegozafermin is an FGF21 analog in Phase III development for MASH, with topline data from (F4) expected in 2028, respecvely. Phase III study in severe hypertriglyceridemia are also ancipated in Q1 2026. We ulmately view the acquision as a strong strategic fit that broadens Roche’s CVRM pipeline and provides oponality for future combinaon approaches. Of note, the Company has historically been interested in targeng the FGF21 pathway (its FGFR1c/β-Klotho receptor agonist was terminated in Phase II for tachyphylaxis), has several incren agonists from the Carmot acquision, and recently iniated development of afimkibart (an-TL1A) in MASH.
Canaccord Genuity
$73
Buy
58.01%
Upside
Reiterated
09/18/25
Morgan Stanley
$84
Buy
81.82%
Upside
Reiterated
09/18/25
Analysts Are Bullish on These Healthcare Stocks: Scholar Rock Holding (SRRK), Akero Therapeutics (AKRO)We believe the deal provides positive readthrough to Akero's EFX highlighting further interest in the FGF21 mechanism as a target for treating MASH. 11:51 AM GMTM Update 2 M Inc (AKRO.O) Our PT is derived from a discounted cash flow (DCF) analysis, including risk-adjusted revenues for EFX in NASH that assumes a 12.5% discount rate and a 0% terminal growth rate. Risks to Upside n Better than expected clinical data.
H.C. Wainwright
$72
Buy
55.84%
Upside
Initiated
09/04/25
Bank of America Securities
$64
Buy
38.53%
Upside
Reiterated
08/25/25
Evercore ISI
$60
Buy
29.87%
Upside
Initiated
08/22/25
TD Cowen
$76
Buy
64.50%
Upside
Reiterated
08/08/25
J.P. Morgan
$69→$68
Buy
47.19%
Upside
Reiterated
05/14/25
Jefferies
$75
Buy
62.34%
Upside
Reiterated
05/13/25
Clear Street
$49
Buy
6.06%
Upside
Initiated
04/29/25
Westpark Capital
$72→$75
Buy
62.34%
Upside
Reiterated
02/28/25
Phillip Securities
$80
Buy
73.16%
Upside
Reiterated
02/28/25
UBS
$42→$109
Buy
135.93%
Upside
Reiterated
01/31/25
Best Analysts Covering Akero Therapeutics
1 Month
xxx
Success Rate
8/10 ratings generated profit
Average Return
+12.25%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +12.25% per trade.
3 Months
xxx
Success Rate
13/21 ratings generated profit
Average Return
+13.44%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +13.44% per trade.
1 Year
Success Rate
6/9 ratings generated profit
Average Return
+36.63%
reiterated a buy rating 2 days ago
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +36.63% per trade.
2 Years
xxx
Success Rate
11/14 ratings generated profit
Average Return
+41.07%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +41.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AKRO Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Aug 25
Sep 25
Strong Buy
12
5
8
13
16
Buy
10
5
5
7
6
Hold
5
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
10
13
20
23
Each month's total comprises the sum of three months' worth of ratings.
AKRO Financial Forecast
AKRO Stock Forecast FAQ
What is AKRO’s average 12-month price target, according to analysts?
Based on analyst ratings, Akero Therapeutics Inc’s 12-month average price target is 72.71.
What is AKRO’s upside potential, based on the analysts’ average price target?
Akero Therapeutics Inc has 57.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AKRO a Buy, Sell or Hold?
Akero Therapeutics Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Akero Therapeutics Inc’s price target?
The average price target for Akero Therapeutics Inc is 72.71. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $84.00 ,the lowest forecast is $60.00. The average price target represents 57.38% Increase from the current price of $46.2.
The highest analyst price target is $84.00 ,the lowest forecast is $60.00. The average price target represents 57.38% Increase from the current price of $46.2.
What do analysts say about Akero Therapeutics Inc?
Akero Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of AKRO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.